Antibody-Drug Conjugate MYK-3 for EGFR-Mutated NSCLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR-targeted therapies for non-small cell lung cancer (NSCLC) face challenges due to rapid mutations in the EGFR kinase domain, leading to drug resistance, and the limitations of PD-1/PD-L1 checkpoint blockade therapy in treating EGFR-mutated NSCLC.
Innovation Solution
The use of an antibody-drug conjugate (ADC) such as MYK-3, which combines an anti-EGFR antibody with a cytotoxic agent linked by a specific linker, shows significant pharmacodynamic effects in inhibiting tumor growth in NSCLC cell lines and PDX models with EGFR mutations. Additionally, the combination of MYK-3 with an anti-PD-1 antibody like AK103 demonstrates synergistic effects in inhibiting tumor growth in AZD9291-resistant NSCLC models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGFR-targeted TKIs are used to treat NSCLC, then tumor growth is inhibited initially, but drug resistance develops due to mutations in the EGFR kinase domain
Solution Approach 1:
The patent segments the therapeutic approach by combining two distinct mechanisms: EGFR-targeted ADC therapy and PD-1/PD-L1 immune checkpoint blockade. This segmentation allows simultaneous attack on tumor cells through direct cytotoxicity and immune-mediated destruction, preventing single-mechanism resistance
Solution Approach 2:
The patent creates a composite therapeutic regimen combining an EGFR-targeted antibody-drug conjugate (MYK-3) with PD-1/PD-L1 inhibitors. This composite approach integrates targeted delivery of cytotoxic agents with immune system activation, producing synergistic effects that overcome mutation-driven resistance
2Reliability
If PD-1/PD-L1 checkpoint inhibitors are used to treat NSCLC, then immune response is enhanced, but efficacy is limited in EGFR-mutated tumors
Solution Approach 1:
The patent merges EGFR-targeted ADC therapy with PD-1/PD-L1 immune checkpoint blockade into a unified treatment regimen. The ADC component targets EGFR-mutated tumors directly while the immune checkpoint inhibitor enhances immune recognition, creating a synergistic effect that overcomes the limited efficacy of single-agent therapy in this patient population
3Reliability
If new TKIs are developed to overcome EGFR mutations, then resistance is temporarily overcome, but mutations occur faster than drug development
Solution Approach 1:
The patent applies preliminary action by combining multiple therapeutic mechanisms upfront rather than sequentially switching drugs after resistance develops. The dual mechanism of EGFR-targeted ADC plus immune checkpoint blockade creates immediate multi-pronged pressure on the tumor, preventing the rapid emergence of resistance that occurs with single-mechanism therapies
Solution Approach 2:
The patent changes the therapeutic parameters by transitioning from small-molecule TKIs to an antibody-drug conjugate with different binding characteristics and cytotoxic mechanisms. This parameter change, combined with immune system activation, creates a new therapeutic profile that is not susceptible to mutations that confer resistance against conventional TKIs
Data Source
AI summary
The present application relates to the use of an antibody-drug conjugate, and a combined drug and the use thereof. Specifically provided are the use of an antibody-drug conjugate, a combined drug and the use thereof. The antibody-drug conjugate shows a significant pharmacodynamic effect of inhibiting tumor cell growth in various NSCLC cell lines with EGFR mutation expression and various human NSCLC PDX tumor models of AZD9291 drug resistance with EGFR mutation expression. In addition, the combined administration of the antibody-drug conjugate and an anti-PD-1 antibody or an anti-PD-L1 antibody shows a significant synergistic pharmacodynamic effect of inhibiting tumor cell growth in the human NSCLC PDX tumor model of AZD9291 drug resistance with EGFR mutation expression.